NCT01633970 - A Study of Atezolizumab Administered in Combination With Bevacizumab and/or With Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors | Biotech Hunter

Enrollment

240

Participants

Timeline

Start Date

July 11, 2012

Primary Completion Date

February 26, 2020

Study Completion Date

February 26, 2020

Conditions

Cancer

Interventions

DRUG

5-FU

Participants will receive 5-FU 400 mg/m\^2 IV q2w.

DRUG

Atezolizumab

Participants will receive IV atezolizumab (800 mg q2w or 1200 mg q3w) q3w.

DRUG

Bevacizumab

Participants will receive bevacizumab 10 mg/kg or 15 mg/kg IV q3w.

DRUG

Carboplatin

Participants will receive carboplatin IV q3w with target AUC of 6 mg/mL.

DRUG

Leucovorin

Participants will receive leucovorin 400 mg/m\^2 IV q2w.

DRUG

Nab-paclitaxel

Participants will receive nab-paclitaxel 100 mg/m\^2 IV qw.

DRUG

Oxaliplatin

Participants will receive oxaliplatin 85 mg/m\^2 IV q2w.

DRUG

Paclitaxel

Participants will receive paclitaxel 200 mg/m\^2 IV q3w.

DRUG

Pemetrexed

Participants will receive pemetrexed 500 mg/m\^2 IV q3w.

Trial Locations (11)

10016

Laura and ISAAC Perlmutter Cancer Center at NYU Langone., New York

20007

Georgetown University Medical Center Lombardi Cancer Center, Washington D.C.

27705

Duke University Medical Center, Durham

28078

Carolina BioOncology Institute; Can Therapy & Res Ctr, Huntersville

37203

Sarah Cannon Research Inst., Nashville

60637

Uni of Chicago, Chicago

80045

University of Colorado Cancer Center, Aurora

06511

Yale University, New Haven

02114

Massachusetts General Hospital., Boston

02215

Beth Israel Deaconess Med Ctr, Boston

Dana Farber Can Ins, Boston